Centre for Health Studies and Research of University of Coimbra/Centre for Innovative Biomedicine and Biotechnology, Faculty of Economics of University of Coimbra, Coimbra, Portugal.
Neurology Department of Coimbra University Hospital Centre, Faculty of Medicine of University of Coimbra, Coimbra, Portugal.
BMC Neurol. 2021 Feb 6;21(1):58. doi: 10.1186/s12883-021-02085-z.
Migraine Disability Assessment Scale (MIDAS) is a useful tool to measure headache-related disability. Modified MIDAS with 4-week recall period reduces recall bias and improves accuracy of the results. This study aimed at validating mMIDAS in Portuguese.
Studied population consisted of adult migraine patients attending a headache outpatient clinic. Reliability was assessed by internal consistency and reproducibility in a 3-week test-retest. Content validity was evaluated by two expert panels. Construct validity was tested by comparing mMIDAS-P index in socioeconomic and clinical patient groups and scale unidimensionality was evidenced by factor analysis. Criterion validity was tested using EQ-5D-5L and HADS.
Ninety-two patients, 88% female, mean age of 44 years, participated. They had, in average, 9.7 headache days in previous month, pain averaging 7.5/10. About 69.9% were on a migraine prophylactic treatment, and 42.4% had severe disability; 29.4 and 13.0% showed, respectively, moderate/severe anxiety and depression. Content validity showed that mMIDAS-P is simple and clinically useful. It did not show to be determined by patient's sociodemographic characteristics and it was correlated with depression scale and EQ-5D-5L. Test-retest demonstrated high reproductive reliability and good internal consistency.
mMIDAS-P is valid and reliable. We strongly recommend it for clinical and research use.
偏头痛残疾评估量表（MIDAS）是一种用于测量头痛相关残疾的有用工具。采用 4 周回顾期的改良 MIDAS 可减少回忆偏倚并提高结果的准确性。本研究旨在验证葡萄牙语版 mMIDAS 的有效性。
研究人群由头痛门诊就诊的成年偏头痛患者组成。在 3 周的测试-重测中评估了可靠性，包括内部一致性和可重复性。通过两个专家小组评估内容效度。通过比较社会经济和临床患者组的 mMIDAS-P 指数来检验构念效度，并通过因子分析证明量表的单一维度。采用 EQ-5D-5L 和 HADS 来检验效标效度。
92 名患者，88%为女性，平均年龄为 44 岁，平均每月头痛 9.7 天，疼痛平均评分为 7.5/10。约 69.9%的患者正在接受偏头痛预防性治疗，42.4%的患者存在严重残疾；分别有 29.4%和 13.0%的患者表现出中度/重度焦虑和抑郁。内容效度表明，mMIDAS-P 简单且具有临床实用性。它不受患者社会人口统计学特征的影响，与抑郁量表和 EQ-5D-5L 相关。测试-重测显示出较高的可重复性和良好的内部一致性。
mMIDAS-P 具有有效性和可靠性。我们强烈推荐它用于临床和研究用途。
